Artiva Biotherapeutics Statistics
Total Valuation
ARTV has a market cap or net worth of $224.18 million. The enterprise value is $127.11 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, before market open.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ARTV has 24.72 million shares outstanding. The number of shares has increased by 117.11% in one year.
| Current Share Class | 24.72M |
| Shares Outstanding | 24.72M |
| Shares Change (YoY) | +117.11% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 8.33% |
| Owned by Institutions (%) | 12.95% |
| Float | 4.27M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.00 |
| P/TBV Ratio | 2.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.61 |
| Quick Ratio | 8.31 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.55% and return on invested capital (ROIC) is -34.87%.
| Return on Equity (ROE) | -56.55% |
| Return on Assets (ROA) | -32.97% |
| Return on Invested Capital (ROIC) | -34.87% |
| Return on Capital Employed (ROCE) | -76.21% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$806,394 |
| Employee Count | 104 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +267.21% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +267.21% |
| 50-Day Moving Average | 6.91 |
| 200-Day Moving Average | 4.38 |
| Relative Strength Index (RSI) | 51.53 |
| Average Volume (20 Days) | 358,790 |
Short Selling Information
The latest short interest is 148,487, so 0.60% of the outstanding shares have been sold short.
| Short Interest | 148,487 |
| Short Previous Month | 148,199 |
| Short % of Shares Out | 0.60% |
| Short % of Float | 3.47% |
| Short Ratio (days to cover) | 0.78 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -89.81M |
| Pretax Income | -83.87M |
| Net Income | -83.87M |
| EBITDA | -87.21M |
| EBIT | -89.81M |
| Earnings Per Share (EPS) | -$3.43 |
Full Income StatementBalance Sheet
The company has $108.01 million in cash and $10.94 million in debt, giving a net cash position of $97.07 million or $3.93 per share.
| Cash & Cash Equivalents | 108.01M |
| Total Debt | 10.94M |
| Net Cash | 97.07M |
| Net Cash Per Share | $3.93 |
| Equity (Book Value) | 109.97M |
| Book Value Per Share | 4.53 |
| Working Capital | 99.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$76.75 million and capital expenditures -$2.59 million, giving a free cash flow of -$79.34 million.
| Operating Cash Flow | -76.75M |
| Capital Expenditures | -2.59M |
| Depreciation & Amortization | 2.60M |
| Net Borrowing | -132,000 |
| Free Cash Flow | -79.34M |
| FCF Per Share | -$3.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |